Big Pharma is currently undergoing a significant surge in mergers and acquisitions (M&A), described as a "deal fever" by financial analysts. This heightened activity is primarily fueled by the looming "patent cliff," where major pharmaceutical companies face the expiration of patents on several top-selling drugs. For example, Merck's cancer drug Keytruda, which accounts for over half of its revenue, is set to lose exclusivity in 2028. This impending loss of exclusivity (LOE) could expose over $300 billion in revenue for the sector over the next five years, creating an urgent need for companies to acquire new drug candidates to maintain growth and offset revenue gaps.
The M&A landscape in 2026 is characterized by a record-breaking pace, with biotech dealmaking on track for a bumper year. The first quarter alone saw biotech M&A deal values reach $84 billion, a significant increase from $44.4 billion the previous year and the strongest start since 2019. If this pace continues, the total biopharma M&A value for 2026 could exceed $250 billion, potentially making it the second-highest year on record, surpassed only by 2019's $328 billion driven by mega-mergers like Bristol Myers Squibb's acquisition of Celgene. Analysts attribute this surge not just to a rebound from pre-COVID levels, but to a more durable trend.
Several factors beyond patent expirations are contributing to this M&A boom. These include deep cash reserves held by large pharmaceutical companies, attractive valuations of biotech firms, a wave of newly approved drugs, and increasing confidence in navigating regulatory scrutiny. Companies like Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, facilitating acquisitions. Eli Lilly, Gilead Sciences, and Merck have been among the most active acquirers this year. The current environment, with strategic urgency, tighter private funding for biotechs, and an uncertain IPO market, has created a "perfect environment for accelerated dealmaking," according to Patrice Mesnier of Oldenburg Capital Partners.
The focus of these acquisitions is often on mid-sized biotech firms and bolt-on transactions, particularly in high-growth therapeutic areas such as oncology, immunology, neurology, cardiovascular disease, and obesity. Companies are also showing strong interest in firms leveraging artificial intelligence and machine learning for drug discovery and clinical development. While the biotech IPO window is slowly reopening, tighter exit strategies for many biotechs still make M&A an attractive option. The urgency to replenish pipelines will remain a key driver, with large-cap pharma actively seeking to acquire late-stage programs to address revenue gaps and ensure future growth. This is evident in the fact that future global revenue exposed to patent expiry over the next seven years is approximately 2.5 times higher than that in the last 16 years, signaling a sustained period of M&A activity.
